Skip to content

Adipose Tissue Extract and Platelet-rich Plasma Use for Wound Healing

The Effect of Adipose Tissue Extract and Platelet-rich Plasma on Split-thickness Donor Site Wound Healing. A Comparative Study

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02799290
Enrollment
24
Registered
2016-06-14
Start date
2015-06-30
Completion date
2016-05-31
Last updated
2021-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wound Healing Disturbance of

Brief summary

Adipose Tissue Extract (ATE) has been found to be an autologous source of growth factors with proven in vitro angiogenic and adipogenic properties.It is obtained by a simple lipoaspirate procedure. We sought to compare the effect of ATE with another known source, platelet-rich plasma to compare the wound healing characteristics on skin graft donor sites.

Detailed description

The investigators enrolled 24 participants with an indication for skin graft. Two or more split-thickness grafts are harvested per patient, one serving as control and the other as experimental. The experimental sites were covered with either autologous PRP gel or ATE prepared in the OR, which was selected in an unblinded manner due to surgical theater convenience. However, donor sites were randomized through a computer generator. Covered with a semiocclusive film, wounds were separated and followed up on days 3,5,7,10,14 for wound healing and 30 and 60 for scar evaluation. Digital photography and specto-photocutometry was employed to know the hemoglobin and melanin content of the wounds, and custom-made software was used to calculate the percentage of wound re-epithelialization.

Interventions

BIOLOGICALADIPOSE TISSUE EXTRACT

Adipose tissue extract is obtained on site with lipoaspirate adipose tissue prepared though incubation and filtration

BIOLOGICALPLATELET-RICH PLASMA GEL

Autologous platelet rich plasma is obtained onsite and activated following commercial kit instructions

Sponsors

Tampere University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* donor site indication

Exclusion criteria

* immunosupressive states * terminal renal insufficiency * pregnancy * coagulation dyscrasias * active infection in donor site

Design outcomes

Primary

MeasureTime frameDescription
Wound Re-epithelization30 daysobservational-digital photography with specialized custom-made software

Secondary

MeasureTime frameDescription
Scar Properties30 and 60 daysVancouver Manchester modified scar scale Minimum value 0 maximum value 14 Higher scores mean worse outcome (Scale analyzes 5 wound characteristics in a numeric scale, where 0 is the best scar outcome and 14 the worst. These characteristics are wound: pigmentation, height, vascularity, contour, texture and brightness.) See scale below Vascularity Normal 0 Pink 1 Red 2 Purple 3 Pigmentation Normal 0 Hypopigmentation 1 Hyperpigmentation 2 Height Flat 0 Depressed1 Elevated 2 Matte vs. shine Shine 0 Matte 1 Contour Forms part of the adjacent skin 0 Small indentation or invagination 1 Hypertrophic 2 Keloid 3 Texture Normal 0 Barely palpable 1 Rough 2 Indented 3
Oxygenated Hemoglobinday 30 and 60Spectophotocutometry measurements with specialized digital camera and software analysis measured in estimated concentration changes (ECC). ECC is a ratio of light reflected hemoglobin chromofore on a special diode light camera. The ratio is between the scar and the adjacent normal skin and is an arbitrary scale previously published. From 0 to 1, where 1 are values closest to the adjacent healthy unscarred skin.
Melanin Concentration in Woundday 30 and 60Melanin concentration measured by spectophotocutometry and analyzed by computer software and represented in estimated concentration changes (ECC), as explained above is an arbitrary ratio between the light absorbance between the scar and the adjacent healthy (unscarred skin) for the melanin chromofore.

Countries

Finland

Participant flow

Participants by arm

ArmCount
CONTROL
No intervention
24
ADIPOSE TISSUE EXTRACT
Adipose Tissue extract application ADIPOSE TISSUE EXTRACT: Adipose tissue extract is obtained on site with lipoaspirate adipose tissue prepared though incubation and filtration
13
PLATELET-RICH PLASMA GEL
PLATELET RICH PLASMA GEL APPLICATION PLATELET-RICH PLASMA GEL: Autologous platelet rich plasma is obtained onsite and activated following commercial kit instructions
11
Total48

Baseline characteristics

CharacteristicCONTROLADIPOSE TISSUE EXTRACTPLATELET-RICH PLASMA GELTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
11 Participants3 Participants9 Participants23 Participants
Age, Categorical
Between 18 and 65 years
13 Participants10 Participants2 Participants25 Participants
Age, Continuous59 years
STANDARD_DEVIATION 16.82
56.07 years
STANDARD_DEVIATION 16.57
62.45 years
STANDARD_DEVIATION 17.23
59 years
STANDARD_DEVIATION 16.82
Sex: Female, Male
Female
6 Participants3 Participants3 Participants12 Participants
Sex: Female, Male
Male
18 Participants10 Participants8 Participants36 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 240 / 130 / 11
other
Total, other adverse events
0 / 240 / 130 / 11
serious
Total, serious adverse events
0 / 240 / 130 / 11

Outcome results

Primary

Wound Re-epithelization

observational-digital photography with specialized custom-made software

Time frame: 30 days

Population: Measured as a whole per group as mean and standard deviation of group and not participant healing.

ArmMeasureValue (NUMBER)
CONTROLWound Re-epithelization12.34 days
ADIPOSE TISSUE EXTRACTWound Re-epithelization10.27 days
PLATELET-RICH PLASMA GELWound Re-epithelization11.33 days
Secondary

Melanin Concentration in Wound

Melanin concentration measured by spectophotocutometry and analyzed by computer software and represented in estimated concentration changes (ECC), as explained above is an arbitrary ratio between the light absorbance between the scar and the adjacent healthy (unscarred skin) for the melanin chromofore.

Time frame: day 30 and 60

ArmMeasureGroupValue (MEAN)Dispersion
CONTROLMelanin Concentration in WoundDAY 300.02 Arbitrary unitsStandard Deviation 0.02
CONTROLMelanin Concentration in WoundDAY 600.01 Arbitrary unitsStandard Deviation 0.01
ADIPOSE TISSUE EXTRACTMelanin Concentration in WoundDAY 600.02 Arbitrary unitsStandard Deviation 0.04
ADIPOSE TISSUE EXTRACTMelanin Concentration in WoundDAY 300.03 Arbitrary unitsStandard Deviation 0.03
PLATELET-RICH PLASMA GELMelanin Concentration in WoundDAY 300.03 Arbitrary unitsStandard Deviation 0.03
PLATELET-RICH PLASMA GELMelanin Concentration in WoundDAY 600.02 Arbitrary unitsStandard Deviation 0.02
CONTROL PRPMelanin Concentration in WoundDAY 300.03 Arbitrary unitsStandard Deviation 0.03
CONTROL PRPMelanin Concentration in WoundDAY 600.03 Arbitrary unitsStandard Deviation 0.03
Secondary

Oxygenated Hemoglobin

Spectophotocutometry measurements with specialized digital camera and software analysis measured in estimated concentration changes (ECC). ECC is a ratio of light reflected hemoglobin chromofore on a special diode light camera. The ratio is between the scar and the adjacent normal skin and is an arbitrary scale previously published. From 0 to 1, where 1 are values closest to the adjacent healthy unscarred skin.

Time frame: day 30 and 60

ArmMeasureGroupValue (MEAN)Dispersion
CONTROLOxygenated HemoglobinDay 300.36 Arbitrary unitsStandard Deviation 0.18
CONTROLOxygenated HemoglobinDay 600.18 Arbitrary unitsStandard Deviation 0.3
ADIPOSE TISSUE EXTRACTOxygenated HemoglobinDay 600.19 Arbitrary unitsStandard Deviation 0.11
ADIPOSE TISSUE EXTRACTOxygenated HemoglobinDay 300.20 Arbitrary unitsStandard Deviation 0.22
PLATELET-RICH PLASMA GELOxygenated HemoglobinDay 300.24 Arbitrary unitsStandard Deviation 0.31
PLATELET-RICH PLASMA GELOxygenated HemoglobinDay 600.09 Arbitrary unitsStandard Deviation 0.17
CONTROL PRPOxygenated HemoglobinDay 300.28 Arbitrary unitsStandard Deviation 0.25
CONTROL PRPOxygenated HemoglobinDay 600.01 Arbitrary unitsStandard Deviation 0.16
Secondary

Scar Properties

Vancouver Manchester modified scar scale Minimum value 0 maximum value 14 Higher scores mean worse outcome (Scale analyzes 5 wound characteristics in a numeric scale, where 0 is the best scar outcome and 14 the worst. These characteristics are wound: pigmentation, height, vascularity, contour, texture and brightness.) See scale below Vascularity Normal 0 Pink 1 Red 2 Purple 3 Pigmentation Normal 0 Hypopigmentation 1 Hyperpigmentation 2 Height Flat 0 Depressed1 Elevated 2 Matte vs. shine Shine 0 Matte 1 Contour Forms part of the adjacent skin 0 Small indentation or invagination 1 Hypertrophic 2 Keloid 3 Texture Normal 0 Barely palpable 1 Rough 2 Indented 3

Time frame: 30 and 60 days

Population: Modified Vancouver/Manchester scar scale at 30 days

ArmMeasureGroupValue (MEAN)Dispersion
CONTROLScar PropertiesDAY 308.13 units on a scaleStandard Deviation 2.795
CONTROLScar PropertiesDAY 605.66 units on a scaleStandard Deviation 2.8
ADIPOSE TISSUE EXTRACTScar PropertiesDAY 304.86 units on a scaleStandard Deviation 2.13
ADIPOSE TISSUE EXTRACTScar PropertiesDAY 602.4 units on a scaleStandard Deviation 2.2
PLATELET-RICH PLASMA GELScar PropertiesDAY 603.23 units on a scaleStandard Deviation 2.4
PLATELET-RICH PLASMA GELScar PropertiesDAY 306.46 units on a scaleStandard Deviation 2.53
CONTROL PRPScar PropertiesDAY 306.85 units on a scaleStandard Deviation 2.23
CONTROL PRPScar PropertiesDAY 605.69 units on a scaleStandard Deviation 2.2

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026